Trials / Completed
CompletedNCT02228681
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
A Randomized Phase II Trial of Everolimus and Letrozole or Hormonal Therapy (Tamoxifen/Medroxyprogesterone Acetate) in Women With Advanced, Recurrent, or Persistent Endometria Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 74 (actual)
- Sponsor
- GOG Foundation · Network
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the effectiveness of the combination of the drugs Everolimus and Letrozole compared to Tamoxifen and Medroxyprogesterone acetate in treating endometrial cancer and to determine the types and severity of side effects caused by treatment with these drug combinations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus | 10mg daily by mouth |
| DRUG | Tamoxifen | 20 mg daily by mouth on alternating weeks (even numbered) weeks |
| DRUG | Letrozole | 2.5mg once a day by mouth |
| DRUG | Medroxyprogesterone Acetate | 200 mg daily by mouth |
Timeline
- Start date
- 2015-05-21
- Primary completion
- 2018-01-01
- Completion
- 2024-08-22
- First posted
- 2014-08-29
- Last updated
- 2024-09-19
- Results posted
- 2019-05-24
Locations
26 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02228681. Inclusion in this directory is not an endorsement.